Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit
satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation …

Short-term symptomatic treatment and dose-dependent side effects of pharmacological
treatment for neurodegenerative diseases have forced the medical community to seek an …

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by decreased
synaptic transmission and cerebral atrophy with appearance of amyloid plaques and …

Neurodegeneration and depression are two common co-morbid conditions, particularly
within the aging population. Research has linked neuroinflammation as a major contributing …

Background The gut microbiota (GM) and brain are strongly associated, which significantly
affects neuronal development and disorders. GM-derived metabolites modulate neuronal …

No drug has been approved to prevent neuronal cell loss in patients suffering from
Parkinson's disease (PD) or Alzheimer's disease (AD); despite increased comprehension of …

The increase of many deadly diseases like infections by multidrug-resistant bacteria implies
re-inventing the wheel on drug discovery. A better comprehension of the metabolisms and …

Computational approaches are very necessary and useful resources in the process of drug
development. The goal of drug development is to identify a chemical compound that can fit …

Reversal of aging symptoms and related disorders are the challenging task where
epigenetic is a crucial player that includes DNA methylation, histone modification; chromatin …

Highlights•Parkinson's disease (PD) is a neurodegenerative disorder with complex
pathophysiological pathways.•The one-drug–single-target approach is inadequate in …